Bristol-Myers Squibb Company
BMY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.43 | -4.24 | -0.11 |
| FCF Yield | 12.16% | 11.92% | 7.80% | 11.00% |
| EV / EBITDA | 49.08 | 7.03 | 9.62 | 8.45 |
| Quality | ||||
| ROIC | 14.49% | 10.59% | 9.61% | 8.93% |
| Gross Margin | 56.80% | 56.34% | 57.39% | 57.69% |
| Cash Conversion Ratio | -1.70 | 1.72 | 2.06 | 2.31 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.52% | -1.00% | 2.78% | 21.06% |
| Free Cash Flow Growth | 10.20% | 5.88% | -21.57% | 14.55% |
| Safety | ||||
| Net Debt / EBITDA | 12.90 | 1.55 | 1.64 | 1.57 |
| Interest Coverage | 4.96 | 7.27 | 7.53 | 7.15 |
| Efficiency | ||||
| Inventory Turnover | 8.16 | 7.38 | 8.41 | 9.37 |
| Cash Conversion Cycle | 90.72 | 112.70 | 97.20 | 82.60 |